Peptide Based Hematological Disorders Therapeutics Market Expected to Secure Notable Revenue Share during 2017-2022

Due to the advances in technology, the manufacturers and suppliers are encouraged to seek novel methods for peptide manufacturing, which is bound to improve the production of longer and complex chain of peptides and reduce the cost of production. Moreover, due to the automation of instruments, with improvements in the purification process and reduction in the total waste generated, are the driving factors triggering the growth of the global peptide therapeutics market. However, the synthesis and purification of long peptides is challenging for the manufacturers. Also, the rise in modifications and the addition of more unnatural amino acids have further increased the complications in peptide synthesis. This makes the manufactures of peptides difficult, and therefore the gap between demand and supply is increasing. Also, the manufacturing of peptides is a costly process, which hampers the growth of the global peptide therapeutics market.

Get Free Sample Report here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=189

Haematological disorders are the disorders related to problems in blood and blood components such as red blood cells, white blood cells, platelets, blood vessels, lymph nodes, spleen, bone marrow and the problems related to the proteins involved in bleeding and clotting (haemostasis and thrombosis). Therapeutic peptides are used in the treatment of haematological disorders mentioned above. Peptides are short chains of amino acid monomers linked by peptide (amide) bonds. Such type of covalent chemical bonds are formed when the carboxyl group of one amino acid reacts with the amino group of another. Peptides are differentiated from proteins on the basis of size, and peptides contain 50 amino acids or less approximately. 

This Fact.MR report on the global peptide based hematological disorders therapeutics market forecasts that the global peptide based hematological disorders therapeutics market will touch a value of nearly US$ 530 Mn in the year 2022 and grow at a robust CAGR during the assessment period.

4 Forecast Highlights on Global Peptide Based Hematological Disorders Therapeutics Market

As per the forecast of Fact.MR, the ecallantide segment is slated to touch a value of nearly US$ 120 Mn in the year 2022. This represents a robust CAGR growth during the assessment period of 2017-2022. The ecallantide segment is estimated to account for more than one-fifth of the revenue share of the drug segment by the year 2017 end and is expected to gain in market share by the year 2022 end.

As per the forecast of Fact.MR, the retail pharmacies segment will reach a value of nearly US$ 115 Mn in the year 2017. This represents a robust CAGR growth during the forecast period. The retail pharmacies segment is estimated to account for more than one-third of the revenue share of the distribution channel segment in the year 2017 end and is expected to gain market share by the end of the year 2022.  

As per the forecast of Fact.MR, by the end of 2022, North America peptide based hematological disorders therapeutics market is projected to reach nearly US$ 220 Mn, registering a robust CAGR over the forecast period.

As perFact.MR forecasts, the US peptide based hematological disorders therapeutics market is estimated to account for 88.6% revenue share of the global peptide based hematological disorders therapeutics market by 2017 end and is expected to gain in market share by 2022 over 2017.

Know the methodology behind the report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=189

Icatibant Segment Poised to Touch a Value of Nearly US$ 410 Mn in 2022

As per the forecast of Fact.MR, the icatibant segment is expected to reach a value of nearly US$ 410 Mn in the year 2022. This represents a robust CAGR during the forecast period of 2017-2022. Icatibant segment is expected to account for more than three-fourth of the revenue share of the drug segment by the year 2017 and is expected to lose market share by the end of the year 2022.  

Hospital Pharmacies Segment to exhibit a CAGR of 7.4% During the Assessment Period

As per the forecast of Fact.MR, the hospital pharmacies segment is slated to touch a figure of nearly US$ 260 Mn in the year 2022. This represents a CAGR of 7.4% during the assessment period from 2017 till the year 2022. This segment is expected to lose market share by the end of the year 2022. The hospital pharmacies segment is expected to account for more than half of the revenue share of the distribution channel segment by the year 2017.

Competition Tracking

The report also profiles companies that are expected to remain active in the expansion of global peptide based hematological disorders therapeutics market through 2022, which includes Shire plc.

Grow Your Business From Expert Advice @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=189

Table of Content:

Global Peptide Based Hematological Disorders Therapeutics Market - Executive Summary
Global Peptide Based Hematological Disorders Therapeutics Market Overview
2.1. Introduction
     2.1.1. Global Peptide Based Hematological Disorders Therapeutics Market Taxonomy
     2.1.2. Global Peptide Based Hematological Disorders Therapeutics Market Definition
2.2. Global Peptide Based Hematological Disorders Therapeutics Market Size (US$ Mn) and Forecast, 2012-2022
       2.2.1. Global Peptide Based Hematological Disorders Therapeutics Market Y-o-Y Growth
2.3. Global Peptide Based Hematological Disorders Therapeutics Market Dynamics
2.4. Regulations
2.5. Supply Chain
2.6. Cost Structure
2.7. Average Pricing Analysis 
2.8. Epidemiology
2.9. Key Participants Market Presence (Intensity Map) By Region
Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Drug 
3.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Drug, 2012-2022
     3.1.1. Icatibant Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
              3.1.1.1. Revenue (US$ Mn) Comparison, By Region
                3.1.1.2. Market Share Comparison, By Region
                3.1.1.3. Y-o-Y growth Comparison, By Region
       3.1.2. Ecallantide Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region
                3.1.2.2. Market Share Comparison, By Region
                3.1.2.3. Y-o-Y growth Comparison, By Region
Global Peptide Based Hematological Disorders Therapeutics Market Analysis and Forecast By Distribution Channel 
4.1. Global Peptide Based Hematological Disorders Therapeutics Market Size and Forecast By Distribution Channel, 2012-2022
     4.1.1. Hospital Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
              4.1.1.1. Revenue (US$ Mn) Comparison, By Region
                4.1.1.2. Market Share Comparison, By Region
                4.1.1.3. Y-o-Y growth Comparison, By Region
       4.1.2. Retail Pharmacies Peptide Based Hematological Disorders Therapeutics Market Size and Forecast, 2012-2022
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region
Continued……………..

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.